Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: Implications for their infusion across major HLA barriers

Dario Sangiolo, Emanuela Martinuzzi, Maja Todorovic, Katiuscia Vitaggio, Antonella Vallario, Noela Jordaney, Fabrizio Carnevale-Schianca, Antonio Capaldi, Massimo Geuna, Laura Casorzo, Richard A. Nash, Massimo Aglietta, Alessandro Cignetti

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Donor-derived cytokine-induced killer (CIK) can be infused as adoptive immunotherapy after hematopoietic cell transplant (HCT). Promising results were recently reported in HLA-identical HCT, where mild grafts versus host (GVH) events were observed. To extend this strategy across major HLA barriers (e.g. HLA-haploidentical HCT), further studies on CIK cells' alloreactivity are needed. We hypothesized that alloreactivity and anti-tumor activity of CIK cells segregate within two different cell subsets and could consequently be separated according to CD56 and CD3 expression. We tested CIK cells expanded from seven patients who underwent HCT as treatment of metastatic colorectal cancer. We found that CIK cells maintained their alloreactivity across major HLA barriers when tested as bulk population; after CD56-positive selection, anti-tumor activity was restricted to the CD3+/CD56+ cell fraction and alloreactivity versus HLA-mismatched PBMC was restricted to the CD3+/ CD56- cell fraction. Bulk CIK cells from engrafted patients did not exhibit alloreactivity in response to host- or donor-derived PBMC, confirming their low potential for GVH across minor HLA barriers. Moreover, we tested if CIK cells expanded from engrafted patients after HCT were as effective as donor-derived ones and could be considered as an alternative option. The expansion rate and tumor cell killing was comparable to that observed in sibling donors. In conclusion, depletion of CD3+/CD56- cells might reduce the risk of GVH without affecting the tumor-killing capacity and could help extending CIK infusions across major HLA barriers. Engrafted patients after HCT could also be considered as an effective alternative option to donor-derived CIK cells.

Original languageEnglish
Pages (from-to)841-848
Number of pages8
JournalInternational Immunology
Volume20
Issue number7
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Cytokine-Induced Killer Cells
Transplants
Neoplasms
Tissue Donors
Cytokines
Adoptive Immunotherapy
Siblings
Colorectal Neoplasms

Keywords

  • DLI
  • GVHD
  • GVT
  • Haploidentical transplant

ASJC Scopus subject areas

  • Immunology

Cite this

Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells : Implications for their infusion across major HLA barriers. / Sangiolo, Dario; Martinuzzi, Emanuela; Todorovic, Maja; Vitaggio, Katiuscia; Vallario, Antonella; Jordaney, Noela; Carnevale-Schianca, Fabrizio; Capaldi, Antonio; Geuna, Massimo; Casorzo, Laura; Nash, Richard A.; Aglietta, Massimo; Cignetti, Alessandro.

In: International Immunology, Vol. 20, No. 7, 07.2008, p. 841-848.

Research output: Contribution to journalArticle

Sangiolo, Dario ; Martinuzzi, Emanuela ; Todorovic, Maja ; Vitaggio, Katiuscia ; Vallario, Antonella ; Jordaney, Noela ; Carnevale-Schianca, Fabrizio ; Capaldi, Antonio ; Geuna, Massimo ; Casorzo, Laura ; Nash, Richard A. ; Aglietta, Massimo ; Cignetti, Alessandro. / Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells : Implications for their infusion across major HLA barriers. In: International Immunology. 2008 ; Vol. 20, No. 7. pp. 841-848.
@article{965bd76fc27d4d248370c2d46d9efbc1,
title = "Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: Implications for their infusion across major HLA barriers",
abstract = "Donor-derived cytokine-induced killer (CIK) can be infused as adoptive immunotherapy after hematopoietic cell transplant (HCT). Promising results were recently reported in HLA-identical HCT, where mild grafts versus host (GVH) events were observed. To extend this strategy across major HLA barriers (e.g. HLA-haploidentical HCT), further studies on CIK cells' alloreactivity are needed. We hypothesized that alloreactivity and anti-tumor activity of CIK cells segregate within two different cell subsets and could consequently be separated according to CD56 and CD3 expression. We tested CIK cells expanded from seven patients who underwent HCT as treatment of metastatic colorectal cancer. We found that CIK cells maintained their alloreactivity across major HLA barriers when tested as bulk population; after CD56-positive selection, anti-tumor activity was restricted to the CD3+/CD56+ cell fraction and alloreactivity versus HLA-mismatched PBMC was restricted to the CD3+/ CD56- cell fraction. Bulk CIK cells from engrafted patients did not exhibit alloreactivity in response to host- or donor-derived PBMC, confirming their low potential for GVH across minor HLA barriers. Moreover, we tested if CIK cells expanded from engrafted patients after HCT were as effective as donor-derived ones and could be considered as an alternative option. The expansion rate and tumor cell killing was comparable to that observed in sibling donors. In conclusion, depletion of CD3+/CD56- cells might reduce the risk of GVH without affecting the tumor-killing capacity and could help extending CIK infusions across major HLA barriers. Engrafted patients after HCT could also be considered as an effective alternative option to donor-derived CIK cells.",
keywords = "DLI, GVHD, GVT, Haploidentical transplant",
author = "Dario Sangiolo and Emanuela Martinuzzi and Maja Todorovic and Katiuscia Vitaggio and Antonella Vallario and Noela Jordaney and Fabrizio Carnevale-Schianca and Antonio Capaldi and Massimo Geuna and Laura Casorzo and Nash, {Richard A.} and Massimo Aglietta and Alessandro Cignetti",
year = "2008",
month = "7",
doi = "10.1093/intimm/dxn042",
language = "English",
volume = "20",
pages = "841--848",
journal = "International Immunology",
issn = "0953-8178",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells

T2 - Implications for their infusion across major HLA barriers

AU - Sangiolo, Dario

AU - Martinuzzi, Emanuela

AU - Todorovic, Maja

AU - Vitaggio, Katiuscia

AU - Vallario, Antonella

AU - Jordaney, Noela

AU - Carnevale-Schianca, Fabrizio

AU - Capaldi, Antonio

AU - Geuna, Massimo

AU - Casorzo, Laura

AU - Nash, Richard A.

AU - Aglietta, Massimo

AU - Cignetti, Alessandro

PY - 2008/7

Y1 - 2008/7

N2 - Donor-derived cytokine-induced killer (CIK) can be infused as adoptive immunotherapy after hematopoietic cell transplant (HCT). Promising results were recently reported in HLA-identical HCT, where mild grafts versus host (GVH) events were observed. To extend this strategy across major HLA barriers (e.g. HLA-haploidentical HCT), further studies on CIK cells' alloreactivity are needed. We hypothesized that alloreactivity and anti-tumor activity of CIK cells segregate within two different cell subsets and could consequently be separated according to CD56 and CD3 expression. We tested CIK cells expanded from seven patients who underwent HCT as treatment of metastatic colorectal cancer. We found that CIK cells maintained their alloreactivity across major HLA barriers when tested as bulk population; after CD56-positive selection, anti-tumor activity was restricted to the CD3+/CD56+ cell fraction and alloreactivity versus HLA-mismatched PBMC was restricted to the CD3+/ CD56- cell fraction. Bulk CIK cells from engrafted patients did not exhibit alloreactivity in response to host- or donor-derived PBMC, confirming their low potential for GVH across minor HLA barriers. Moreover, we tested if CIK cells expanded from engrafted patients after HCT were as effective as donor-derived ones and could be considered as an alternative option. The expansion rate and tumor cell killing was comparable to that observed in sibling donors. In conclusion, depletion of CD3+/CD56- cells might reduce the risk of GVH without affecting the tumor-killing capacity and could help extending CIK infusions across major HLA barriers. Engrafted patients after HCT could also be considered as an effective alternative option to donor-derived CIK cells.

AB - Donor-derived cytokine-induced killer (CIK) can be infused as adoptive immunotherapy after hematopoietic cell transplant (HCT). Promising results were recently reported in HLA-identical HCT, where mild grafts versus host (GVH) events were observed. To extend this strategy across major HLA barriers (e.g. HLA-haploidentical HCT), further studies on CIK cells' alloreactivity are needed. We hypothesized that alloreactivity and anti-tumor activity of CIK cells segregate within two different cell subsets and could consequently be separated according to CD56 and CD3 expression. We tested CIK cells expanded from seven patients who underwent HCT as treatment of metastatic colorectal cancer. We found that CIK cells maintained their alloreactivity across major HLA barriers when tested as bulk population; after CD56-positive selection, anti-tumor activity was restricted to the CD3+/CD56+ cell fraction and alloreactivity versus HLA-mismatched PBMC was restricted to the CD3+/ CD56- cell fraction. Bulk CIK cells from engrafted patients did not exhibit alloreactivity in response to host- or donor-derived PBMC, confirming their low potential for GVH across minor HLA barriers. Moreover, we tested if CIK cells expanded from engrafted patients after HCT were as effective as donor-derived ones and could be considered as an alternative option. The expansion rate and tumor cell killing was comparable to that observed in sibling donors. In conclusion, depletion of CD3+/CD56- cells might reduce the risk of GVH without affecting the tumor-killing capacity and could help extending CIK infusions across major HLA barriers. Engrafted patients after HCT could also be considered as an effective alternative option to donor-derived CIK cells.

KW - DLI

KW - GVHD

KW - GVT

KW - Haploidentical transplant

UR - http://www.scopus.com/inward/record.url?scp=45749097431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749097431&partnerID=8YFLogxK

U2 - 10.1093/intimm/dxn042

DO - 10.1093/intimm/dxn042

M3 - Article

C2 - 18469328

AN - SCOPUS:45749097431

VL - 20

SP - 841

EP - 848

JO - International Immunology

JF - International Immunology

SN - 0953-8178

IS - 7

ER -